Herzlia, Israel and Calgary, Alberta–(Newsfile Corp. – March 10, 2021) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC Pink: INNPF) (the “Company” or “Innocan”) filed an international patent application for a novel cannabis-based Anti-itch treatment. The composition is comprised of a pharmaceutically effective amount of a cannabinoid and active ingredients to aid in the relief of itching associated with insect bites, rash, cuts, burns or by exposure to various allergens.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/76622
Powered by WPeMatico
